Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.41 |
| ▸ | HTR1D | P28221 | 6/20 | 0.41 |
| ▸ | HTR1B | P28222 | 6/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25034808 | 0.91 | GRM5 (0.36) | HTR1AHTR1DHTR1BSQORVCP | |
| SCHEMBL30981151 | 0.91 | GRM5 (0.36) | HTR1AHTR1DHTR1BSQORVCP | |
| SCHEMBL25819578 | 0.86 | HTR1A (0.45) | HTR1AHTR1DHTR1BGABRG2GABRB3 | |
| SCHEMBL25819581 | 0.84 | MAPT (0.51) | — | |
| SCHEMBL30817336 | 0.80 | GRM5 (0.38) | SQORHRH4F10GRM5 | |
| SCHEMBL25819162 | 0.80 | CKS1B (0.47) | VCP | |
| SCHEMBL25034811 | 0.77 | MAPT (0.49) | — | |
| SCHEMBL25482345 | 0.77 | LRRK2 (0.43) | HTR1AHTR1DHTR1BGABRG2GABRB3 | |
| SCHEMBL26641363 | 0.76 | HTR7 (0.36) | HTR1AHTR1DHTR1BHRH4VCP | |
| SCHEMBL25819197 | 0.76 | L3MBTL1 (0.44) | SQOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | HTR1A 4156/4885HTR1D 4288/4885HTR1B 4222/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | HTR1A 2866/4885HTR1D 3081/4885HTR1B 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.